<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00017212</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068663</org_study_id>
    <secondary_id>DAIICHI-8951A-PRT028</secondary_id>
    <secondary_id>SACI-IDD-00-27</secondary_id>
    <secondary_id>UTHSC-0015011134</secondary_id>
    <nct_id>NCT00017212</nct_id>
  </id_info>
  <brief_title>DX-8951f in Treating Patients With Metastatic Stomach Cancer</brief_title>
  <official_title>A Phase II Study Of Intravenous Exatecan Mesylate (DX-891F) Administered Daily For Five Days Every Three Weeks To Patients With Previously Untreated Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients&#xD;
      who have metastatic stomach cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective response rate of patients with previously untreated metastatic&#xD;
           gastric cancer treated with exatecan mesylate (DX-8951f).&#xD;
&#xD;
        -  Determine the time to tumor progression in this patient population when treated with&#xD;
           this drug.&#xD;
&#xD;
        -  Determine the survival at 6 and 12 months in this patient population when treated with&#xD;
           this drug.&#xD;
&#xD;
        -  Determine the quantitative and qualitative toxic effects of this drug in this patient&#xD;
           population.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in the plasma of these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive exatecan mesylate (DX-8951f) IV over 30 minutes on days 1-5. Treatment&#xD;
      repeats every 21 days for at least 2 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">September 2003</completion_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exatecan mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed gastric or gastroesophageal adenocarcinoma&#xD;
&#xD;
               -  Lymph node involvement and/or distant metastasis&#xD;
&#xD;
          -  No squamous cell carcinoma, small cell carcinoma, lymphoma, or leiomyosarcoma of the&#xD;
             stomach&#xD;
&#xD;
          -  Measurable disease with indicator lesions outside the field of prior radiotherapy&#xD;
&#xD;
               -  At least 20 mm by conventional scan OR&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
               -  Nonmeasurable lesions include the following:&#xD;
&#xD;
                    -  Primary tumor&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural/pericardial effusion&#xD;
&#xD;
                    -  Inflammatory breast disease&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonitis&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
                    -  Abdominal masses not confirmed and followed by imaging techniques&#xD;
&#xD;
          -  No prior treatment for locally advanced or metastatic disease&#xD;
&#xD;
               -  Prior adjuvant treatment allowed if disease recurrence noted at least 6 months&#xD;
                  after completion of adjuvant treatment&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  AST or ALT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver&#xD;
             metastases present)&#xD;
&#xD;
          -  Albumin at least 2.8 g/dL&#xD;
&#xD;
          -  PT or INR no greater than 1.5 times ULN (coumadin independent)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No active congestive heart failure&#xD;
&#xD;
          -  No uncontrolled angina&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent serious infection&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No overt psychosis, mental disability, or incompetence that would preclude informed&#xD;
             consent&#xD;
&#xD;
          -  No other life-threatening illness&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent anti-cancer biologic therapy&#xD;
&#xD;
          -  No concurrent prophylactic colony stimulating factors during first course of therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Recovered from prior adjuvant chemotherapy&#xD;
&#xD;
          -  No other concurrent anti-cancer chemotherapy&#xD;
&#xD;
          -  No other concurrent anti-cancer cytotoxic therapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent megestrol for appetite stimulation allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior wide-field radiotherapy to more than 25% of bone marrow&#xD;
&#xD;
          -  No concurrent anti-cancer radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery and recovered&#xD;
&#xD;
          -  No concurrent anti-cancer surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other investigational drugs (including analgesics or antiemetics) for at least 4&#xD;
             weeks prior to, during, and for 4 weeks after study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert L. DeJager, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Shores Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-9154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3264</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario-Hamilton Regional Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ajani JA, Takimoto C, Becerra CR, Silva A, Baez L, Cohn A, Major P, Kamida M, Feit K, De Jager R. A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Invest New Drugs. 2005 Oct;23(5):479-84.</citation>
    <PMID>16133799</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 15, 2012</last_update_submitted>
  <last_update_submitted_qc>May 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exatecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

